SCHEMBL4407653

SCHEMBL4407653

NC(CCC1=CCCC1)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 3/20 0.44
GRIA4 P48058 3/20 0.44
GRIK5 Q16478 3/20 0.44
GRIA3 P42263 2/20 0.44
GRIK1 P39086 3/20 0.42
GRIA2 P42262 2/20 0.42
GRIK3 Q13003 2/20 0.42
GRM8 O00222 1/20 0.42
GRM6 O15303 1/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GSR P00390 1/20 0.42
CYP1A2 P05177 1/20 0.42
GRM5 P41594 1/20 0.42
SLC1A3 P43003 1/20 0.42
SLC1A2 P43004 1/20 0.42
SLC1A1 P43005 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIK2 Q13002 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14485771 0.82 GRIA1 (0.52) GRIA1GRIA4GRIK5GRIA3GRIK1
SCHEMBL615017 0.82 GRIA1 (0.52) GRIA1GRIA4GRIK5GRIA3GRIK1
SCHEMBL939749 0.82 GRIA1 (0.52) GRIA1GRIA4GRIK5GRIA3GRIK1
SCHEMBL6255381 0.77 GRIA1 (0.48) GRIA1GRIA4GRIK5GRIA3GRIK1
SCHEMBL4757741 0.77 GRIA1 (0.48) GRIA1GRIA4GRIK5GRIA3GRIK1
SCHEMBL20821107 0.76 SMN1; SMN2 (0.39) GRIA1GRIA4GRIK5GRIA3SMN1; SMN2
SCHEMBL5298700 0.76 GRIA1 (0.47) GRIA1GRIA4GRIK5GRIA3GRIK1
SCHEMBL1342487 0.76 SMN1; SMN2 (0.49) SMN1; SMN2NPSR1KMT2ATAAR1MAPK1
SCHEMBL9623345 0.74 HPGD (0.46) SMN1; SMN2NPSR1KMT2ATAAR1ALDH1A1
SCHEMBL5324248 0.71 GRM2 (0.41) GRIA1GRIA4GRIK5GRIA3GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090180958-A1 Diagnostic and therapeutic agents KARYON-CTT LTD. (FI) 2009-07-16 US disclosed
EP-1874800-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS Karyon-CTT Ltd (FI) 2008-01-09 EP disclosed
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed
WO-2006114478-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090180958-A1 Diagnostic and therapeutic agents TPX2, ZFX, ZYX GRIA1 1388/4885GRIA4 2621/4885GRIK5 1238/4885
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 GRIA1 3993/4885GRIA4 4357/4885GRIK5 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.